Key result
Ivabradine fails to improve exercise capacity compared to placebo.
Why the study?
Few proven therapies exist to improve exercise capacity in patients with TGA after atrial switch repair, leaving the effect of heart rate lowering with ivabradine on exercise capacity and quality of life in this population uncertain.
Does heart rate lowering with ivabradine improve peak oxygen consumption and quality of life in adults with transposition of the great arteries post-atrial switch repair?
RCT (n=10)
Double-blind
1:1 fashion using an online generator of randomly permuted blocks, crossover design
No
Does heart rate lowering with ivabradine improve peak oxygen consumption and quality of life in adults with transposition of the great arteries post-atrial switch repair?
In adults with transposition of the great arteries post-atrial switch repair, ivabradine significantly reduced resting and peak exercise heart rate and increased peak oxygen pulse, with a borderline non-significant trend toward improved peak oxygen consumption.
Answers are grounded in this paper and cite their sources.
Does not support ivabradine for peak VO2 improvement in post-atrial switch TGA; leaves open efficacy on exercise capacity despite HR and oxygen pulse effects.
BACKGROUND: There are few proven therapies for improving exercise capacity in patients with transposition of the great arteries who have undergone an atrial switch repair. OBJECTIVES: The objective of the study was to evaluate the effect of heart rate lowering using ivabradine on exercise capacity and quality of life in this cohort. METHODS: In this single-center, randomized, double-blind, crossover study, patients were randomized to ivabradine or placebo for 4 weeks then crossover treatment for 4 weeks. A cardiopulmonary stress test and quality of life assessment were performed at baseline then at weeks 4 and 8. Estimates of difference were described using a mixed effects model. RESULTS: A total of 19 patients were eligible and 10 patients completed the study. Compared to placebo, ivabradine treatment was associated with lower heart rate at baseline (65 ± 3 beats/min on ivabradine vs 79 ± 5 beats/min on placebo, difference -14.6 [-24, -5]; P = 0.008) and at peak exercise (131 ± 7 beats/min vs 146 ± 7 beats/min, difference -15.3 [-24, -6]; P = 0.003). Peak oxygen consumption was 20.4 ± 1.2 mL/kg/min on ivabradine vs 19.2 ± 1.2 mL/kg/min on placebo (difference +1.2 [-0.09, 2.6]; P = 0.06). Peak oxygen pulse was higher on ivabradine compared to placebo (12.5 ± 1.2 vs 10.7 ± 1.2 mL/beat, difference +1.7 [0.9, 2.6]; P = 0.002). Visual analog score was 73.5 ± 5.6 on ivabradine vs 62.5 ± 5.6 on placebo (mean difference 11.0 [-1.6, 23.6]; P = 0.08). One patient developed symptomatic bradycardia and one patient experienced phosphenes. CONCLUSIONS: Ivabradine use in patients with transposition of the great arteries and atrial switch repair lowered peak heart rate with exercise and was associated with a higher oxygen pulse. (Effect of Ivabradine use on exercise capacity in patients with transposition of the great arteries [TGA] post atrial switch repair; ACTRN12621000196842).
No takes yet. Share an insight, caveat, or question.
WILSON et al. (2026) conducted an RCT in Transposition of the great arteries (TGA) post-atrial switch repair (n=10). Ivabradine vs. Placebo (over-encapsulated identical capsules) was evaluated on Peak oxygen consumption (VO2, mL/kg/min) (MD 1.23 mL/kg/min, 95% CI -0.09 to 2.55, p=0.064). Ivabradine did not increase exercise capacity compared to placebo, though it lowered peak heart rate and increased peak oxygen pulse.
Synapse has enriched 10 related papers. Consider them for comparative context: